Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States.
+ 2 more risks
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.03|
|52 Week High||US$0.97|
|52 Week Low||US$6.14|
|1 Month Change||-0.96%|
|3 Month Change||-11.21%|
|1 Year Change||-60.54%|
|3 Year Change||-87.62%|
|5 Year Change||-95.38%|
|Change since IPO||-99.97%|
Recent News & Updates
|IDRA||US Biotechs||US Market|
Return vs Industry: IDRA underperformed the US Biotechs industry which returned 23.4% over the past year.
Return vs Market: IDRA underperformed the US Market which returned 30.7% over the past year.
Stable Share Price: IDRA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: IDRA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
|1989||32||Vinnie, Vin Milano||https://www.iderapharma.com|
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb.
Idera Pharmaceuticals Fundamentals Summary
|IDRA fundamental statistics|
Is IDRA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IDRA income statement (TTM)|
|Cost of Revenue||US$12.58m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.20|
|Net Profit Margin||0.00%|
How did IDRA perform over the long term?See historical performance and comparison
Is Idera Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IDRA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IDRA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IDRA is good value based on its PE Ratio (6.6x) compared to the US Biotechs industry average (24.4x).
PE vs Market: IDRA is good value based on its PE Ratio (6.6x) compared to the US market (17.1x).
Price to Earnings Growth Ratio
PEG Ratio: IDRA's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: IDRA is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (3.1x).
How is Idera Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDRA's earnings are forecast to decline over the next 3 years (-47.7% per year).
Earnings vs Market: IDRA's earnings are forecast to decline over the next 3 years (-47.7% per year).
High Growth Earnings: IDRA's earnings are forecast to decline over the next 3 years.
Revenue vs Market: IDRA is forecast to have no revenue next year.
High Growth Revenue: IDRA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IDRA's Return on Equity is forecast to be high in 3 years time
How has Idera Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDRA has a large one-off loss of $77.3M impacting its June 30 2021 financial results.
Growing Profit Margin: IDRA became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: IDRA has become profitable over the past 5 years, growing earnings by -1.4% per year.
Accelerating Growth: IDRA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: IDRA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: IDRA's Return on Equity (29%) is considered high.
How is Idera Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: IDRA's short term assets ($43.5M) exceed its short term liabilities ($6.0M).
Long Term Liabilities: IDRA's short term assets ($43.5M) exceed its long term liabilities ($656.0K).
Debt to Equity History and Analysis
Debt Level: IDRA is debt free.
Reducing Debt: IDRA has no debt compared to 5 years ago when its debt to equity ratio was 1%.
Debt Coverage: IDRA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: IDRA has no debt, therefore coverage of interest payments is not a concern.
What is Idera Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IDRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IDRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IDRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IDRA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IDRA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Vinnie, Vin Milano (57 yo)
Mr. Vincent J. Milano, also known as Vinnie and Vin, has been a Director of BioCryst Pharmaceuticals, Inc. since July 26, 2021. He has been an Independent Director at Aclaris Therapeutics, Inc. since Janua...
CEO Compensation Analysis
Compensation vs Market: Vinnie, Vin's total compensation ($USD1.35M) is above average for companies of similar size in the US market ($USD545.00K).
Compensation vs Earnings: Vinnie, Vin's compensation has been consistent with company performance over the past year.
Experienced Management: IDRA's management team is considered experienced (2.9 years average tenure).
Experienced Board: IDRA's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IDRA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.9%.
Idera Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Idera Pharmaceuticals, Inc.
- Ticker: IDRA
- Exchange: NasdaqCM
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$54.345m
- Shares outstanding: 52.76m
- Website: https://www.iderapharma.com
Number of Employees
- Idera Pharmaceuticals, Inc.
- 505 Eagleview Boulevard
- Suite 212
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 04:58|
|End of Day Share Price||2021/09/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.